DAMORA THERAPEUTICS, INC. Preferred Stock, Shares Outstanding
DAMORA THERAPEUTICS, INC. (DMRA) had Preferred Stock, Shares Outstanding of 0 shares as of 2024-09-30, per its 10-Q filed 2024-11-01.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockSharesOutstanding · last filed 2024-11-01
- 2024-09-30: Preferred Stock, Shares Outstanding 0.00 shares.
- 2024-06-30: Preferred Stock, Shares Outstanding 0.00 shares.
- 2024-03-31: Preferred Stock, Shares Outstanding 0.00 shares.
- 2023-12-31: Preferred Stock, Shares Outstanding 0.00 shares.
| Period end | Preferred Stock, Shares Outstanding |
|---|---|
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-01 |
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-12 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-04-29 |
| 2023-12-31 | 0.00 shares 10-Q · filed 2024-11-01 |
| 2023-09-30 | 0.00 shares 10-Q · filed 2023-11-06 |
| 2023-06-30 | 0.00 shares 10-Q · filed 2023-07-31 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-04-28 |
| 2022-12-31 | 0.00 shares 10-K · filed 2024-03-08 |
| 2022-09-30 | 0.00 shares 10-Q · filed 2022-11-08 |
| 2022-06-30 | 0.00 shares 10-Q · filed 2022-07-29 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-04-29 |
| 2021-12-31 | 0.00 shares 10-K · filed 2023-03-09 |
| 2021-09-30 | 0.00 shares 10-Q · filed 2021-11-04 |
| 2021-06-30 | 0.00 shares 10-Q · filed 2021-08-05 |
| 2021-03-31 | 0.00 shares 10-Q · filed 2021-05-04 |
| 2020-12-31 | 0.00 shares 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |